Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Entrada Therapeutics, Inc. (TRDA : NSDQ)

• Company Description    Entrada Therapeutics Inc. is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles(TM) to engage intracellular targets. Entrada Therapeutics Inc. is based in BOSTON. Number of Employees: 183

• Price / Volume Information    Yesterday's Closing Price: $6.76 Daily Weekly Monthly 20 Day Moving Average: 139,083 shares Shares Outstanding: 37.95 (millions) Market Capitalization: $256.57 (millions) Beta: -0.11 52 Week High: $21.79 52 Week Low: $6.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -13.89% -17.11% 12 Week -16.85% -30.06% Year To Date -60.90% -63.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One Design Center Place Suite 17-500 - Boston,MA 02210 USA ph: 857-520-9158 fax: - investors@entradatx.com http://www.entradatx.com

• General Corporate Information    Officers Dipal Doshi - Chief Executive Officer Kush M. Parmar - Chairman Kory Wentworth - Chief Financial Officer Gina Chapman - Director Peter S. Kim - Director Peer Information Entrada Therapeutics, Inc. (CORR.) Entrada Therapeutics, Inc. (RSPI) Entrada Therapeutics, Inc. (CGXP) Entrada Therapeutics, Inc. (BGEN) Entrada Therapeutics, Inc. (GTBP) Entrada Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 29384C108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 37.95 Most Recent Split Date: (:1) Beta: -0.11 Market Capitalization: $256.57 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.93 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.18 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 8.35 PEG Ratio: - Price Ratios Price/Book: 0.61 Price/Cash Flow: 4.26 Price / Sales: 1.49 EPS Growth vs. Year Ago Period: -161.76% vs. Previous Quarter: -1,500.00% Sales Growth vs. Year Ago Period: -65.23% vs. Previous Quarter: -45.03% ROE 06/30/25 - - 03/31/25 - 5.84 12/31/24 - 16.93 ROA 06/30/25 - - 03/31/25 - 4.61 12/31/24 - 12.08 Current Ratio 06/30/25 - - 03/31/25 - 21.88 12/31/24 - 11.15 Quick Ratio 06/30/25 - - 03/31/25 - 21.88 12/31/24 - 11.15 Operating Margin 06/30/25 - - 03/31/25 - 14.39 12/31/24 - 31.14 Net Margin 06/30/25 - - 03/31/25 - 14.39 12/31/24 - 31.14 Pre-Tax Margin 06/30/25 - - 03/31/25 - 13.82 12/31/24 - 31.54 Book Value 06/30/25 - - 03/31/25 - 10.99 12/31/24 - 11.46 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©